PCI Biotech: Fourth quarter and preliminary 2018 results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
52
PCI Biotech: Fourth quarter and preliminary 2018 results

Oslo (Norway), 13 February 2019 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim fourth quarter and preliminary 2018 result. Please find enclosed the report and presentation.

Solid performance through 2018, moving towards initiation of the pivotal “RELEASE” study

The fully underwritten rights issue of NOK 360 million completed in October 2018 provides PCI Biotech with the funds needed for the pivotal fima Chem study, beyond interim read-out of results for potential accelerated/conditional marketing approval. The pivotal study, which for further communication purposes will be called “RELEASE”, is expected to start in the first half of 2019.

The dose-escalation part of the Phase I study has provided positive early signs of efficacy, with a median overall survival of 21.7 months for the dose selected for the pivotal study. Although the data sample is small, the results with a single fima Chem treatment indicate a clear improvement over the best comparable published data.

Preliminary confirmation of safety with two treatments was reached in Q4 in the Phase I extension study, without the report of any adverse reactions that would limit the delivery of up to two treatments in the RELEASE study. PCI Biotech’s focus is now to bring fima Chem to the market for the treatment of inoperable bile duct cancer through successful completion of the RELEASE study.

The translation of the vaccination technology, fima Vacc , into humans by demonstrating improvement of immunogenicity of vaccines in a Phase 1 study in healthy volunteers is a main priority for PCI Biotech to establish the company in the immunotherapy field.  The dose-finding part of the Phase I study identified a well-tolerated dosing regimen and the interim data suggest enhancement of several parameters of importance for vaccination. PCI Biotech is collaborating with international experts to finalise and publish the in-depth analysis and characterisation of the immune responses from Phase I.

The fima NAc programme continued positive development, with two new research collaborations established and the research collaboration with an undisclosed top-10 pharma company was extended twice during 2018.

On the corporate side, the clinical organisation and the Scientific Advisory Committee have both been reinforced to ensure continued progress in our key areas in 2019.

Per Walday, CEO of PCI Biotech, comments: ”The efficacy results achieved in bile duct cancer are encouraging and the preliminary confirmation that it is safe to repeat the treatment further strengthens the positive prospects of the fima Chem development programme. The company is now all set to initiate the RELEASE trial and fully focused on successful completion of this transforming study.  The positive interim data on T-cell responses with fima Vacc are further supported by initial data suggesting a CD8 T-cell response component.  The response hurdle was set high by the selection of a vaccine antigen that it is notoriously difficult to induce CD8 T-cell responses with in man and it is encouraging to see that a majority of the subjects in the two analysed fima Vacc groups are responders. Immunotherapy is a complex and rapidly progressing field and the immunological expertise in the Scientific Advisory committee has been further reinforced with cutting edge competence by the addition of Professor van der Burg.”

Highlights

* Completed fully underwritten rights issue of NOK 360 million

* Preparations for the pivotal RELEASE study progressing towards initiation in the first half of 2019

* Continued positive early signs of efficacy from fima Chem Phase I dose-escalation

* Preliminary confirmation of safety read-out from the Phase I extension study

* Presented Phase I dose-escalation fima Chem results at the 2018 ESMO congress and at the annual conference of the US CCA Foundation in Jan 2019 (subsequent event)

* Phase I interim fima Vacc data suggest enhancement of several parameters of importance for vaccination

* US patent granted for “band-aid-like“ device for fima Vacc skin illumination / injection

* Extension of preclinical fima NAc research collaboration agreement with a top-10 large pharma company

* Further strengthened the clinical organisation and the Scientific Advisory Committee

***

A presentation in English will be held today, Wednesday 13 February 2019, at Oslo Cancer Cluster Innovation Park.

Time: Wednesday 13 February 2019, 08.30am - 09.30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo.

The presentation can be followed as a live webcast (access through link http://webtv.hegnar.no/presentation.php?webcastId=97603030 ) or the company’s website under “Investors – Reports and presentations – Webcasts”. It will be possible to post questions through the webcast console.

About PCI Biotech           PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fima Chem (enhancement of chemotherapeutics for localised treatment of cancer), fima Vacc (T-cell induction technology for therapeutic vaccination), and fima NAc (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fima Chem programme is about to initiate the RELEASE study, a pivotal clinical trial with the potential of accelerated / conditional marketing approval as a first-line treatment given the rare disease status and unmet medical need. fima Vacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fima NAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For more information visit: www.pcibiotech.com           Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                 Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757

Forward-looking statements   This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 174

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 127

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 65

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 69

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 252

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 7

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

NVIDIA Set to Gain from Hyperscalers' Surge in AI Investments

Updated Category News Views 191

Massive Capital Expenditures Expected from Hyperscalers Recently, major hyperscalers have reported impressive third-quarter financial results, leading to significant updates regarding their capital expenditure (CapEx) plans as the AI market expands. Analysts are observing a dramatic increase in spending plans, with projections indicating that these companies might...

Continue Reading
JARS Cannabis Enhances Live Music Experience This Summer

Updated Category News Views 140

JARS Cannabis Expands Live Music Partnership The Michigan-based cannabis retailer, JARS Cannabis, is amplifying its engagement this summer by enhancing its partnership with 313 Presents. This strategic move aims to introduce a more vibrant presence at two of the region's iconic music venues: Pine Knob Music Theatre and the Michigan Lottery Amphitheatre at Freedom Hill....

Continue Reading
Significant Insights on Gender Differences in HoFH Research

Updated Category News Views 185

Groundbreaking Research Unveiled in Preventive Cardiology Journal The American Journal of Preventive Cardiology (AJPC) has published a groundbreaking study that delves into the crucial sex-based differences in homozygous familial hypercholesterolemia (HoFH). This pivotal research marks the first issue under the new leadership of Dr. Khurram Nasir as Editor-in-Chief and...

Continue Reading
Sugar Grove Ace Commemorates a Decade of Community Support

Updated Category News Views 90

Celebrate a Milestone: Sugar Grove Ace's 10th Anniversary Sugar Grove Ace is thrilled to celebrate its 10th anniversary with a community event that promises fun, excitement, and gratitude. This special gathering is set to take place on a Saturday in the near future, showcasing the store's dedication to its customers and the local community. Event Highlights The day will...

Continue Reading
Insightful Earnings Preview for Microvast Holdings (MVST)

Updated Category News Views 240

Understanding Microvast Holdings's Earnings Outlook Microvast Holdings (NASDAQ: MVST) is on the brink of releasing its next quarterly earnings report. Investors are eager to see how the company fares as speculation around performance intensifies. Let's delve into what to expect and the key indicators influencing stockholder sentiment. Earnings Expectations for the...

Continue Reading